PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.59
Negative P/E while Healthcare median is -1.14. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
2.30
P/B near Healthcare median of 2.47. Charlie Munger would verify if similar multiples reflect similar business quality.
-8.10
Negative FCF while Healthcare median P/FCF is -4.47. Seth Klarman would investigate cash flow improvement potential.
-8.10
Negative operating cash flow while Healthcare median P/OCF is -3.99. Seth Klarman would investigate operational improvement potential.
2.30
Fair value ratio near Healthcare median of 2.48. Charlie Munger would verify if industry valuation norms make sense.
-15.75%
Negative earnings while Healthcare median yield is -2.63%. Seth Klarman would investigate path to profitability.
-12.35%
Negative FCF while Healthcare median yield is -3.05%. Seth Klarman would investigate cash flow improvement potential.